Jérôme Berger announced as strategy and finance executive at Vect-Horus
Natalia Elliot | January 28, 2025 | Appointment | | appointment, private biotechnology company
Vect-Horus, a private biotechnology company specialising in molecular development, has announced the appointment of Jérôme Berger to its board of directors.
Mr Berger bring experience from his previous role at Orange Group as president and managing partner. From this role, he garnered experience by overseeing investments in technology start-ups. As global head of financing and treasury, Mr Berger was responsible for funding operations, managing equity and debt markets and leading infrastructure financing initiatives, including but not limited to the execution of several international, multi-billion dollar mergers and acquisitions. He currently serves as global head of Strategy and Venture Capital at Orange Group.
Alexandre Tokay co-founder and CEO of Vect-Horus stated: “We are thrilled to welcome Jérôme Berger to our board of directors, as Vect-Horus is poised to enter its next phase of growth. Jérôme’s unparalleled experience in strategy, venture capital and global financing, coupled with his strong background in digital health and life sciences, will be invaluable in supporting the development of Vect-Horus as we aim to revolutionise targeted drug delivery.”
Mr Berger has over two decades of experience in the life sciences industry, which Vect-Horus believe will be invaluable in steering the company towards faster growth and development. Mr Berger has previously served as the director for several other biotech companies including Future4Care which was co-founded by Mr Berger during his time at Orange Group in collaboration with Sanofi, Generali and Capgemini.
Natalia Elliot
28/1/25
Related Content
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …
